Placebo and other interventions in asthma.
New England Journal of Medicine (impact factor: 53.3). 10/2011; 365(15):1446; author reply 1447. DOI:10.1056/NEJMc1109235#SA1 pp.1446; author reply 1447
Article: Working with the US Food and Drug Administration: progress and timelines in understanding and treating patients with eosinophilic esophagitis.The Journal of allergy and clinical immunology 09/2012; 130(3):617-9. · 9.17 Impact Factor
Dataset: 2012- TIGERS-FDA editorial
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.